01—Abstract
Summary
Summary of the 10-K filed February 22, 2024. Cited figures are marked; the original filing is the authoritative source.
IDEX Corporation (IEX) reported 2023 net sales of $3,273.9 milliona, up 3% from $3,181.9 million in 2022, with organic net sales declining 1%.
Net income attributable to IDEX was $596.1 millionb, up 2%, and diluted EPS was $7.85 versus $7.71. Adjusted EBITDA rose 2% to $899.6 million, and the company generated record free cash flow of $626.8 million on operating cash flow of $716.7 million. Growth was driven by a 5% contribution from acquisitions net of divestitures and price capture, partially offset by lower volumes, particularly in the Health & Science Technologies segment, as customers destocked inventory.
The company operates three reportable segments: Fluid & Metering Technologies (42% of segment Adjusted EBITDA), Health & Science Technologies (37%), and Fire & Safety/Diversified Products (21%). During 2023 IDEX acquired Iridian Spectral Technologies for $109.8 millionc and STC Material Solutions for $202.0 million, and sold Micropump for $110.3 million, recording a pre-tax gain of $93.8 million. Total borrowings were $1,333.3 million at year-end, with cash and cash equivalents of $534.3 million, and the company was in compliance with its financial covenants, with an interest coverage ratio of 18.43 to 1 and a leverage ratio of 1.45 to 1.
Management stated that the majority of its businesses were seeing stable demand and early signs of improvement, particularly in Fluid & Metering Technologies, while life sciences and analytical instrument markets were not yet showing near-term recovery. The Dispensing reporting unit is expected to contract in 2024 following completion of a North American fleet refreshment cycle in 2023.
02—Key points
Key Highlights
- Net sales rose 3% to $3,273.9 million; organic net sales declined 1% as lower volumes offset price capture.
- Net income attributable to IDEX was $596.1 million, up 2%, with diluted EPS of $7.85 versus $7.71 in 2022.
- Adjusted EBITDA reached $899.6 million, with margin of 27.5% versus 27.9% in 2022.
- Operating cash flow was $716.7 million, up from $557.4 million, and record free cash flow was $626.8 million.
- Acquired Iridian ($109.8 million) and STC ($202.0 million); sold Micropump for $110.3 million with a $93.8 million pre-tax gain.
- Health & Science Technologies adjusted EBITDA fell 13% to $359.5 million as customer destocking reduced volumes.
- Quarterly dividend increased 7% from $0.60 to $0.64 per share; $539.7 million remained under the share repurchase authorization.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2023, Idex kept $0.18.
- Revenue$3.27B100.0%
- Cost of revenue−$1.83B55.8%
- Gross profit$1.45B44.2%
- Operating costs−$714.4M21.8%
- Operating income$732.5M22.4%
- Interest, other & tax−$136.9M4.2%
- Net income$595.6M18.2%
04—Financials
Financial Highlights
Figures from 10-KFY2023filed February 22, 2024Financial Statements
FY2023 against FY2022
| Line item | FY2023FY2022 | Change |
|---|---|---|
| Revenue | $3.27B$3.18B | +2.9% |
| Cost of Revenue | $1.83B$1.75B | +4.1% |
| Gross Profit | $1.45B$1.43B | +1.4% |
| R&D Expenses | $68.40M$61.40M | +11.4% |
| SG&A Expenses | $703.50M$652.70M | +7.8% |
| Operating Income | $732.50M$751.40M | −2.5% |
| Interest Expense | $51.70M$40.70M | +27.0% |
| Net Income | $595.60M$586.70M | +1.5% |
| EPS (Basic) | $7.87$7.74 | +1.7% |
| EPS (Diluted) | $7.85$7.71 | +1.8% |
| Shares Outstanding (Basic) | 75.60M75.70M | −0.1% |
| Shares Outstanding (Diluted) | 75.90M76.00M | −0.1% |
05—Questions
Frequently Asked Questions
How did IDEX perform in 2023 and what drove results?
Net sales grew 3% to $3,273.9 million, driven by a 5% contribution from acquisitions net of divestitures and price capture across all segments. Organic sales declined 1% due to lower volumes from customer inventory recalibration, particularly in Health & Science Technologies. Net income attributable to IDEX increased 2% to $596.1 million.
How strong is IDEX's cash generation and balance sheet?
Cash flows from operating activities were $716.7 million, up from $557.4 million, reflecting lower working capital requirements. Free cash flow was $626.8 million. At year-end, the company held $534.3 million in cash and cash equivalents, $1,333.3 million in total borrowings, and $715.6 million of Revolving Facility availability.
What is the outlook for 2024?
Management said most businesses were experiencing stable demand with early signs of improvement, particularly in Fluid & Metering Technologies. Life sciences and analytical instrument markets, served by about one-third of Health & Science Technologies, appeared stable but were not yet showing near-term recovery. The Dispensing reporting unit is expected to contract in 2024, partly offset by growth in emerging markets and in the Fire & Safety and BAND-IT reporting units.
What acquisitions and divestitures did IDEX complete in 2023?
IDEX acquired Iridian Spectral Technologies in May for $109.8 million and STC Material Solutions in December for $202.0 million, both funded with cash on hand. It sold Micropump on August 3, 2023 for $110.3 million net of cash remitted, recording a pre-tax gain of $93.8 million, and sold Novotema on December 29, 2023 for $8.3 million, recording a loss of $9.1 million.
What are the main risks flagged in the filing?
Risk factors include slowdowns in U.S. or global economies, foreign currency fluctuations (50% of 2023 sales were international), rising interest rates on floating-rate debt, cybersecurity incidents, the ability to execute and integrate acquisitions, raw material and supply chain disruptions, and potential goodwill and intangible asset impairments, which totaled $2,838.3 million and $1,011.8 million respectively at year-end.
06—Continue